{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T06:14:20Z","timestamp":1778739260655,"version":"3.51.4"},"reference-count":27,"publisher":"Informa UK Limited","issue":"4","content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Expert Opinion on Emerging Drugs"],"published-print":{"date-parts":[[2025,10,2]]},"DOI":"10.1080\/14728214.2026.2651330","type":"journal-article","created":{"date-parts":[[2026,4,4]],"date-time":"2026-04-04T18:14:36Z","timestamp":1775326476000},"page":"241-249","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":0,"title":["Gene therapy for wet AMD: a paradigm shift in the standard of care"],"prefix":"10.1080","volume":"30","author":[{"given":"Samuel","family":"Asanad","sequence":"first","affiliation":[{"name":"University of Southern California","place":["Los Angeles, USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David S.","family":"Boyer","sequence":"additional","affiliation":[{"name":"Retina Vitreous-Associates Medical Group","place":["Beverly Hills, USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"301","published-online":{"date-parts":[[2026,4,6]]},"reference":[{"key":"e_1_3_4_3_1","doi-asserted-by":"publisher","DOI":"10.3390\/ijms23052592"},{"key":"e_1_3_4_4_1","doi-asserted-by":"publisher","DOI":"10.4103\/IJO.IJO_1120_24"},{"key":"e_1_3_4_5_1","doi-asserted-by":"publisher","DOI":"10.3390\/ijms25042386"},{"key":"e_1_3_4_6_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41433-021-01842-1"},{"key":"e_1_3_4_7_1","doi-asserted-by":"publisher","DOI":"10.1167\/iovs.17-22233"},{"key":"e_1_3_4_8_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.gt.3301893"},{"key":"e_1_3_4_9_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40259-017-0234-5"},{"key":"e_1_3_4_10_1","doi-asserted-by":"publisher","DOI":"10.3390\/ph16091241"},{"key":"e_1_3_4_11_1","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics13070967"},{"key":"e_1_3_4_12_1","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2022.846782"},{"key":"e_1_3_4_13_1","doi-asserted-by":"publisher","DOI":"10.1186\/s40942-021-00307-7"},{"key":"e_1_3_4_14_1","doi-asserted-by":"publisher","DOI":"10.1089\/jop.2017.0121"},{"key":"e_1_3_4_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.fopow.2025.03.013"},{"key":"e_1_3_4_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2023.102394"},{"key":"e_1_3_4_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(24)00310-6"},{"key":"e_1_3_4_18_1","unstructured":"AbbVie. AbbVie and REGENXBIO announce updates on the ABBV-RGX-314 clinical program. 2025 [cited 2025 Feb 2]. https:\/\/news.abbvie.com\/2025-01-13-AbbVie-and-REGENXBIO-Announce-Updates-on-the-ABBV-RGX-314-Clinical-Program"},{"key":"e_1_3_4_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.omtm.2020.06.007"},{"key":"e_1_3_4_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2018.11.003"},{"key":"e_1_3_4_21_1","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.3005708"},{"key":"e_1_3_4_22_1","doi-asserted-by":"publisher","DOI":"10.1089\/jop.2021.0001"},{"key":"e_1_3_4_23_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0019078"},{"key":"e_1_3_4_24_1","first-page":"732","article-title":"Pooled safety analysis of a single intravitreal injection of JNJ-1887 (gene therapy, AAVCAGsCD59) in patients with age-related macular degeneration (AMD)","volume":"64","author":"Lad EM","year":"2023","unstructured":"Lad EM, Chao DL, Pepio A, et al. Pooled safety analysis of a single intravitreal injection of JNJ-1887 (gene therapy, AAVCAGsCD59) in patients with age-related macular degeneration (AMD). Invest Ophthalmol Visual Sci. 2023;64:732.","journal-title":"Invest Ophthalmol Visual Sci"},{"key":"e_1_3_4_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajo.2019.03.006"},{"key":"e_1_3_4_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)30979-0"},{"key":"e_1_3_4_27_1","unstructured":"Gundecha M. Exegenesis bio announces FDA clearance of investigational New drug (IND) application for EXG102-031: a novel gene therapy for the treatment of neovascular age-related macular degeneration (nAMD). 2023 [cited 2025 Feb 2]. Available from: https:\/\/exegenesisbio.com\/exegenesis-bio-announces-fda-clearance-of-investigational-new-drug-ind-application-for-exg102-031-a-novel-gene-therapy-for-the-treatment-of-neovascular-age-related-macular-degeneration-namd\/"},{"key":"e_1_3_4_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2016.05.054"},{"key":"e_1_3_4_29_1","doi-asserted-by":"publisher","DOI":"10.34133\/research.0717"}],"container-title":["Expert Opinion on Emerging Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/14728214.2026.2651330","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T05:45:40Z","timestamp":1778737540000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/14728214.2026.2651330"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,2]]},"references-count":27,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,10,2]]}},"alternative-id":["10.1080\/14728214.2026.2651330"],"URL":"https:\/\/doi.org\/10.1080\/14728214.2026.2651330","relation":{},"ISSN":["1472-8214","1744-7623"],"issn-type":[{"value":"1472-8214","type":"print"},{"value":"1744-7623","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,2]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=iemd20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=iemd20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2025-04-08","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-03-23","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-04-06","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}